Market Cap | 102.51B | P/E | 7.83 | EPS this Y | - | Ern Qtrly Grth | -17.30% |
Income | 35.37B | Forward P/E | 14.39 | EPS next Y | - | 50D Avg Chg | -5.00% |
Sales | 774.71B | PEG | - | EPS past 5Y | -14.59% | 200D Avg Chg | -11.00% |
Dividend | 9.00% | Price/Book | 0.08 | EPS next 5Y | 62.30% | 52W High Chg | -27.00% |
Recommedations | 2.00 | Quick Ratio | 1.31 | Shares Outstanding | 5.65B | 52W Low Chg | 5.00% |
Insider Own | - | ROA | 0.60% | Shares Float | 5.65B | Beta | 0.75 |
Inst Own | 1.18% | ROE | 7.63% | Shares Shorted/Prior | 619.41K/703.33K | Price | 7.05 |
Gross Margin | 12.45% | Profit Margin | 4.57% | Avg. Volume | 867,725 | Target Price | 10.26 |
Oper. Margin | 6.11% | Earnings Date | - | Volume | 1,187,227 | Change | 0.00% |
China Life Insurance Company Limited, together with its subsidiaries, operates as a life insurance company in the People's Republic of China. The company operates in four segments: Life Insurance Business, Health Insurance Business, Accident Insurance Business, and Other Businesses. It offers critical illness protection, annuity, children/women/pension, security, life, medical, and accident protection insurance products. The company was founded in 1949 and is based in Beijing, the People's Republic of China. China Life Insurance Company Limited is a subsidiary of China Life Insurance (Group) Company Limited.
Goldman Sachs | Sell | Mar 5, 19 |
HSBC | Hold | Jan 22, 19 |
UBS | Neutral | Nov 26, 18 |
Goldman Sachs | Sell | May 10, 18 |
Credit Suisse | Neutral | Aug 25, 17 |
Bank of America | Buy | Aug 25, 17 |
Morgan Stanley | Equal-Weight | Sep 29, 16 |
UBS | Buy | Jul 18, 16 |
UBS | Neutral | Apr 19, 16 |